1 BreimerDD.Interindividual variations in drug disposition.Clinical implications and methods of investigation[J].Clin Pharmacokinet,1983;8:371-7
2 BreimerDD, Schellens JHM.A ' cocktail' strategy to assess in vivo oxidative drug metabolism in humans[J].Trends Pharmacol Sci, 1990;11:223-5
3 Schellens JHM, Ghabrial H, van derWart HHF, BakkerEN,Wilkinson GR, BreimerDD.Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans[J].Clin Pharmacol Ther, 1991;50:520-8
4 Shelepova T, NafzigerAN, Victory J, Kashuba AD, Rowland E,et alZhang Y..Effect of a triphasic oral contraceptive on drugmetabolizing enzyme activity as measured by the validated cooperstown 5 +1 cocktail[J].J Clin Pharmacol, 2005;45:1413-21
5 扈金萍, 闫淑莲, 唐静成, 张锦楠.Cocktail 探针药物评价姜黄对肝细胞色素P450 酶的影响[J].首都医科大学学报, 2004;25:427-30
6 闫淑莲, 扈金萍, 徐艳霞, 张锦楠.Cocktail 探针药物同时评价连翘对肝细胞色素P450 的影响[J].中国药学杂志,2003;38:761-63
7 Liu S, Frye RF, Branch RA, Venkataramanan R, Fung JJ, Burckart GJ.Effect of age and postoperative time on cytochrome p450 enzyme activity following livertransplantation[J].J Clin Pharmacol,2005;45:666-73
8 May CB, Csuka ME, Lupoli S,Wilkinson GR, Branch RA.Activity of oxidative routes of metabolism of debrisoquin, mephenytoin,and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease[J].Clin Pharmacol Ther, 1992;52:659-67
9 Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, et alPersad R..The procarcinogen hypothesis forbladdercancer:activities of individual drug metabolizing enzymes as risk factors[J].Pharmacogenetics, 1995;5:S97-102
10 Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ.Principles and clinical application of assessing alterations in renal elimination pathways[J].Clin Pharmacokinet, 2003;42:1193-211
11 Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE.Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways:absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol[J].BrJ Clin Pharmacol,2001;51:547-55
12 Zhang X, Lalezari JP, Badley AD, DorrA, Kolis SJ, Kinchelow T, et al.Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients[J].Clin Pharmacol Ther, 2004;75:558-68
13 ChristensenM, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al.The Karolinska cocktail forphenotyping of five human cytochrome P450 enzymes[J].Clin Pharmacol Ther, 2003;73:517-28
14 Zhu B, Ou-yang DS, Chen XP, Huang SL, Tan ZR.Assessment of cytochrome P450 activety by a five-drug cocktail approach[J].Clin pharmacol ther, 2001;70:455-61
15 Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M,Aherne Z, et al.Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail forCYPs 1A2, 3A4,Chin J Clin Pharmacol Ther2006 Nov;11(11)
16 2C9, 2D6 and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9 16 Sharma A, Pilote S, BelangerPM, ArsenaultM, Hamelin BA. A convenient five-drug cocktail forthe assessment of majordrug metabolizing enzymes:a pilot study[J]. and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9 16 Sharma A, Pilote S, BelangerPM, ArsenaultM, Hamelin BA. A convenient five-drug cocktail forthe assessment of majordrug metabolizing enzymes:a pilot study[J].BrJ Clin Pharmacol,2004;58:288-97
17 Yin OQ, Lam SS, Lo CM, Chow MS.Rapid determination of five probe drugs and theirmetabolites in human plasma and urine by liquid chromatography tandem mass spectrometry:application to cytochrome P450 phenotyping studies[J].Rapid Commun Mass Spectrom, 2004;18:2921-33
18 Jerdi MC, Daali Y, OestreicherMK, Cherkaoui S, DayerP.A simplified analytical method fora phenotyping cocktail of majorCYP450 biotransformation routes[J].J Pharm Biomed Anal,2004;35:1203-12
19 KrosserS, NeugebauerR, Dolgos H, Fluck M, Rost KL, KovarA.Investigation of sarizotan' s impact on the pharmacokinetics of probe drugs formajorcytochrome P450 isoenzymes:a combined cocktail trial[J].EurJ Clin Pharmaco, 2006;62:277-84
20 WexlerD, Courtney R, Richards W, Banfield C, Lim J, Laughlin M.Effect of posaconazole on cytochrome P450 enzymes:a randomized,open-label, two-way crossoverstudy[J].EurJ Pharm Sci, 2004;21:645-53
21 Scott RJ, PalmerJ, Lewis IA, Pleasance S.Determination of a' GW cocktail' of cytochrome P450 probe substrates and theirmetabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry[J].Rapid Commun Mass Spectrom, 1999;13:2305-19
22 TuckerGT, Houston JB, Huang SM.Optimizing drug development: strategies to assess drug metabolism transporterpotentialtoward a consensus[J].Clin Pharmacol Ther, 2001;70:103-14
23 Food and Drug Administration.FDA Guidance forIndustry:In vivo Drug Metabolism Drug Interaction Studies-Study Design,Data Analysis, and Recommendations forDosing and Labeling[ S].Rockville, MD:FDA, 2005
24 Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M,et alAherne Z..Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail forCYPs 1A2, 3A4,2C9, 2D6 and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9
25 Paolini M, Biagi GL, BauerC, Cantelli-Forti G.Cocktail strategy:complications and limitations[J].J Clin Pharmacol, 1993;33:1011-2
26 Frye RF,Matzke GR, Adedoyin A, PorterJA, Branch RA.Validation of the five-drug “Pittsburgh cocktail” approach forassessment of selective regulation of drug-metabolizing enzymes[J].Clin Pharmacol Ther, 1997;62:365-76 |
